Clinical stage biotech company Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has released a new investor presentation as the company presents at the Ord Minnett Healthcare Forum.
Recce is at the forefront of developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs and emerging viral pathogens.
The company's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327, RECCE® 435, and RECCE® 529. These innovative therapies have the potential to overcome the challenges posed by bacterial and viral mutations that have rendered traditional antibiotics less effective.
The company has multiple near-term clinical readouts due, and multiple clinical indications and formulations in Phase I and Phase II addressing unmet medical needs in sepsis, UTI, burn wounds and diabetic foot ulcer infections.
Strong pipeline
Multiple upcoming clinical milestones
Today’s presentation outlines the company’s multiple upcoming clinical milestones through 2025.
